Non-Hodgkin lymphoma (NHL) is a group of hematologic malignancies that originate from lymphocytes known as B or T cells. This ...
By enrolling the world's first participant, the Sarah Cannon Transplant & Cellular Therapy Program at St. David's South Austin Medical Center made this therapy available to patients before it was ...
Ultrasensitive detection of circulating tumor DNA can improve clinical outcomes in aggressive B-cell lymphomas by identifying measurable residual disease. Defining remission is challenging due to ...
A research team at the University of Cologne's Center for Molecular Medicine Cologne (CMMC) has discovered that the protein ...
PiNACLE – H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator’s choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell ...
Primary mediastinal B-cell lymphoma (PMBCL) is a rare and aggressive type of non-Hodgkin’s lymphoma that originates in the white blood cells behind the breastbone. Although the cause of PMBCL is ...
Lymph nodes are key control centers in the immune system and play an important role in defending the body against infections and tumors. For these processes to function properly, immune cells (B cells ...
Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the intensive chemotherapy often used, according to new research from Sylvester ...
Benjamin Shen, Ph.D., stands within the Natural Products Discovery Center collection at The Wertheim UF Scripps Institute. A powerful anticancer compound was recently discovered within the collection.
In a rare clinical finding, an aggressive diffuse large B-cell non-Hodgkin lymphoma served as the pathological lead point for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results